Cocrystal Pharma (NASDAQ:COCP – Get Free Report) released its earnings results on Friday. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02), FiscalAI reports. The company had revenue of $0.22 million for the quarter.
Cocrystal Pharma Price Performance
Shares of Cocrystal Pharma stock traded down $0.06 during trading on Friday, reaching $1.20. 101,244 shares of the company traded hands, compared to its average volume of 150,678. The company has a 50 day moving average price of $1.27 and a 200-day moving average price of $1.11. Cocrystal Pharma has a 1-year low of $0.86 and a 1-year high of $2.67. The firm has a market capitalization of $16.55 million, a PE ratio of -1.52 and a beta of 1.50.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Cocrystal Pharma stock. DRW Securities LLC acquired a new position in shares of Cocrystal Pharma, Inc. (NASDAQ:COCP – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 33,593 shares of the company’s stock, valued at approximately $33,000. DRW Securities LLC owned about 0.24% of Cocrystal Pharma at the end of the most recent quarter. Institutional investors and hedge funds own 6.72% of the company’s stock.
Cocrystal Pharma Company Profile
Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.
The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.
See Also
- Five stocks we like better than Cocrystal Pharma
- 3 Stocks to Own If Gas Prices Keep Rising
- 3 Crucial Aerospace Component Makers That Analysts Love
- Alphabet’s Googlebook Brings Gemini AI to PC Hardware
- Peloton Stock Gives Back Gains After Upbeat Earnings Report
Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
